Retina Futura
Retina Futura is a new project that will be launched during the FLORetina-ICOOR Meeting 2024, which will be held in Florence (Italy) from 5 to 8 December.
It features an informative and engaging program focused on emerging treatments and innovation in the retina field, where latest results from research and clinical trials will be presented.
It will span across two distinctive 75-minute sessions on Friday, 6 December, integrated within the official Meeting program.
As an add-on to this launch, there will be also a Clinical Trial Reception, on the same day but at 6:00pm, where biopharmaceutical companies will present their ongoing or planned clinical trials that are relevant to our global audience but specifically to the European healthcare ecosystem.
Become part of Retina Futura network!
Discover Retina Futura 2024 Agenda
Latest news
ABBV-RGX-314, a groundbreaking gene therapy under development by RegenxBio and AbbVie, has the potential to transform wet age-related macular degeneration (wet AMD) management. By utilizing an adeno-associated virus serotype 8 (AAV8) vector to deliver a gene encoding an anti-VEGF monoclonal antibody fragment, ABBV-RGX-314 offers a novel approach to sustain VEGF suppression with a single treatment. Two delivery methods are under investigation: subretinal and suprachoroidal administration, each designed to address the significant treatment burden of frequent anti-VEGF injections while reducing the risk for adverse events such as intraocular inflammation.
November 26, 2024
Ocular Therapeutix, Inc. recently announced an accelerated timeline for its Phase 3 SOL-1 clinical trial evaluating AXPAXLI™ (axitinib intravitreal implant) as a potential treatment for wet age-related macular degeneration (wet AMD). The company now expects to complete participant enrollment and randomization by the end of 2024, moving ahead of the initial projections. With this update, topline results from SOL-1 are anticipated by the fourth quarter of 2025, marking a significant milestone for AXPAXLI as an investigational therapy
November 26, 2024
Researchers at the University of Illinois Chicago have developed a promising small-molecule inhibitor that could revolutionize the treatment of wet age-related macular degeneration (AMD). This innovative compound, administered via eye drops, offers a less invasive alternative to the current standard of care, which involves frequent intravitreal injections.
November 26, 2024
The treatment landscape for wet age-related macular degeneration (wAMD) is evolving significantly, with increasing attention on reducing the frequency of intravitreal injections needed to preserve vision. One of the most promising advancements in this area is the EYP-1901, a sustained-release formulation of vorolanib, a tyrosine kinase inhibitor (TKI) delivered via the Durasert platform, which is being investigated in the DAVIO 2 trial.
October 15, 2024
Ocugen’s recent progress in gene therapy for retinitis pigmentosa (RP) represents a major leap forward in treating this debilitating eye disease.
October 15, 2024
